The 5 most recent market catalysts affecting $CLPT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 85
ClearPoint Neuro shares are trading lower after the company reported worse-than-expected Q2 financial results and cut its FY26 sales guidance below estimates.
This headline represents a strong negative corporate catalyst for ClearPoint Neuro. The combination of missing current earnings expectations and significantly lowering future guida…
Aug 3, 2026
Corporate Catalyst
Bearish
Impact 85
ClearPoint Neuro shares are trading lower after the company reported worse-than-expected Q2 financial results and cut its FY26 sales guidance below estimates.
This headline represents a strong negative corporate catalyst for ClearPoint Neuro. The combination of missing current quarter expectations and significantly lowering future guidan…
Aug 3, 2026
Corporate Catalyst
Bearish
Impact 75
ClearPoint Neuro Lowers FY2026 Sales Guidance from $52.000M-$56.000M to $48.000M-$52.000M vs $53.133M Est
ClearPoint Neuro (CLPT) has lowered its sales guidance for fiscal year 2026 from an initial range of $52.000 million-$56.000 million to a new range of $48.000 million-$52.000 milli…
Aug 3, 2026
Corporate Catalyst
Bearish
Impact 95
ClearPoint Neuro Q2 EPS $(0.38) Misses $(0.29) Estimate, Sales $10.880M Miss $12.733M Estimate
ClearPoint Neuro (CLPT) announced its Q2 earnings, reporting a loss of $(0.38) per share, significantly missing the analyst consensus of $(0.29). Additionally, quarterly sales of $…
Jul 31, 2026
Corporate Catalyst
Neutral
Impact 65
ClearPoint Neuro Highlights Partner Aspen Neuroscience’s RMAT Designation From FDA For Parkinson’s Therapy, Sasineprocel
ClearPoint Neuro announced that its partner, Aspen Neuroscience, received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for sasineprocel, an investigationa…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.